Home Icon

Loading, Please Wait...

CST: 19/09/2020 07:40:55   

Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences

572 Days ago

SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that senior management will provide a corporate overview at the upcoming SVB/Leerink Global Healthcare Conference, and the Oppenheimer & Co. 29th Annual Healthcare Conference, both taking place in New York City.

A copy of the presentation materials will be made available on the company website (www.sorrentotherapeutics.com).

SVB/LEERINK Global Healthcare Conference

Date:   Thursday, February 28
Time:   3:30pm Eastern Time
Location:   Lotte New York Palace Hotel
Webcast:   http://investors.sorrentotherapeutics.com/events-and-presentations/events

Oppenheimer & Co. 29 th Annual Healthcare Conference

Date:   Wednesday, March 20
Time:   2:45pm Eastern Time
Location:   Westin Grand Central Hotel, Ambassador Room
Webcast:   http://investors.sorrentotherapeutics.com/events-and-presentations/events

About Sorrento Therapeutics, Inc. 
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and clinical stage oncolytic virus (“Seprehvir®”).

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by its effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. Resiniferatoxin is completing a phase IB trial in terminal cancer patients and a phase 1B trial in osteoarthritis patients.  ZTlido® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com.

Alexis Nahama, SVP Corporate Development
Telephone: 858-203-4120

Dan Ferry
Managing Director
LifeSci Advisors, LLC


We Are Diffrent
Is your business listed correctly on America’s largest city directory network of 1,000 portals?